Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Camp4 Therapeutics (CAMP) EBITDA Margin (2023 - 2025)

Camp4 Therapeutics' EBITDA Margin history spans 3 years, with the latest figure at 11575.86% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 953921.0% year-over-year to 11575.86%; the TTM value through Dec 2025 reached 2298.54%, up 564486.0%, while the annual FY2025 figure was 2298.54%, 564486.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 11575.86% at Camp4 Therapeutics, down from 1899.25% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 15650.6% in Q4 2023 and bottomed at 11575.86% in Q4 2025.
  • The 3-year median for EBITDA Margin is 1674.16% (2025), against an average of 358.51%.
  • The largest annual shift saw EBITDA Margin crashed -1768726bps in 2024 before it plummeted -953921bps in 2025.
  • A 3-year view of EBITDA Margin shows it stood at 15650.6% in 2023, then crashed by -113bps to 2036.66% in 2024, then plummeted by -468bps to 11575.86% in 2025.
  • Per Business Quant, the three most recent readings for CAMP's EBITDA Margin are 11575.86% (Q4 2025), 1899.25% (Q3 2025), and 840.81% (Q2 2025).